Skip to main content
Journal cover image

Cardiorenal interactions: insights from the ESCAPE trial.

Publication ,  Journal Article
Nohria, A; Hasselblad, V; Stebbins, A; Pauly, DF; Fonarow, GC; Shah, M; Yancy, CW; Califf, RM; Stevenson, LW; Hill, JA
Published in: J Am Coll Cardiol
April 1, 2008

OBJECTIVES: We examined the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) database to understand the impact and pathophysiology of renal dysfunction in patients hospitalized with advanced decompensated heart failure (HF). BACKGROUND: Baseline renal insufficiency (RI) (estimated glomerular filtration rate [eGFR] <60 ml/min) and worsening renal function (WRF) (upward arrow serum creatinine [SCr] >or=0.3 mg/dl) during treatment of decompensated HF are associated with adverse outcomes. METHODS: We used a Cox proportional hazards model to evaluate the impact of renal function on 6-month outcomes. Renal parameters were correlated with hemodynamic measurements. The impact of a strategy using pulmonary artery catheter (PAC) guidance on WRF and outcomes in patients with baseline RI was compared with treatment based on clinical assessment alone. RESULTS: Baseline and discharge RI, but not WRF, were associated with an increased risk of death and death or rehospitalization. Among the hemodynamic parameters measured in patients randomized to the PAC arm (n = 194), only right atrial pressure correlated weakly with baseline SCr (r = 0.165, p = 0.03). There was no correlation between baseline hemodynamics or change in hemodynamics and WRF. A PAC-guided strategy was associated with less average increase in creatinine but did not decrease the incidence of defined WRF during hospitalization or affect renal function after discharge relative to clinical assessment alone. CONCLUSIONS: Among patients with advanced decompensated HF, baseline RI impacts outcomes more than WRF. Poor forward flow alone does not appear to account for the development of RI or WRF in these patients. The addition of hemodynamic monitoring to clinical assessment does not prevent WRF or improve renal function after discharge.

Duke Scholars

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

April 1, 2008

Volume

51

Issue

13

Start / End Page

1268 / 1274

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Risk Factors
  • Risk Assessment
  • Renal Insufficiency, Chronic
  • Proportional Hazards Models
  • Prognosis
  • Middle Aged
  • Male
  • Incidence
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nohria, A., Hasselblad, V., Stebbins, A., Pauly, D. F., Fonarow, G. C., Shah, M., … Hill, J. A. (2008). Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol, 51(13), 1268–1274. https://doi.org/10.1016/j.jacc.2007.08.072
Nohria, Anju, Vic Hasselblad, Amanda Stebbins, Daniel F. Pauly, Gregg C. Fonarow, Monica Shah, Clyde W. Yancy, Robert M. Califf, Lynne W. Stevenson, and James A. Hill. “Cardiorenal interactions: insights from the ESCAPE trial.J Am Coll Cardiol 51, no. 13 (April 1, 2008): 1268–74. https://doi.org/10.1016/j.jacc.2007.08.072.
Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol. 2008 Apr 1;51(13):1268–74.
Nohria, Anju, et al. “Cardiorenal interactions: insights from the ESCAPE trial.J Am Coll Cardiol, vol. 51, no. 13, Apr. 2008, pp. 1268–74. Pubmed, doi:10.1016/j.jacc.2007.08.072.
Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, Yancy CW, Califf RM, Stevenson LW, Hill JA. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol. 2008 Apr 1;51(13):1268–1274.
Journal cover image

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

April 1, 2008

Volume

51

Issue

13

Start / End Page

1268 / 1274

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Risk Factors
  • Risk Assessment
  • Renal Insufficiency, Chronic
  • Proportional Hazards Models
  • Prognosis
  • Middle Aged
  • Male
  • Incidence
  • Humans